Statement: None of the patients in cohort 1 of the primary trial had Acute coronary syndrome.
Primary_evidence: Adverse Events 1:   Total: 30/98 (30.61%)   NEUTROPENIA 1/98 (1.02%)   ATRIAL FIBRILLATION 1/98 (1.02%)   CARDIAC FAILURE 1/98 (1.02%)   TACHYCARDIA 0/98 (0.00%)   ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)   VERTIGO 0/98 (0.00%)   ABDOMINAL PAIN 0/98 (0.00%)   COLITIS 0/98 (0.00%)   DIARRHOEA 2/98 (2.04%)   FEMORAL HERNIA 0/98 (0.00%)   HAEMATEMESIS 0/98 (0.00%)   ILEUS 0/98 (0.00%)   NAUSEA 0/98 (0.00%) Adverse Events 2:   Total: 46/102 (45.10%)   NEUTROPENIA 0/102 (0.00%)   ATRIAL FIBRILLATION 0/102 (0.00%)   CARDIAC FAILURE 0/102 (0.00%)   TACHYCARDIA 2/102 (1.96%)   ACUTE VESTIBULAR SYNDROME 0/102 (0.00%)   VERTIGO 1/102 (0.98%)   ABDOMINAL PAIN 2/102 (1.96%)   COLITIS 1/102 (0.98%)   DIARRHOEA 8/102 (7.84%)   FEMORAL HERNIA 1/102 (0.98%)   HAEMATEMESIS 1/102 (0.98%)   ILEUS 1/102 (0.98%)